Saturday Morning Coffee with Experts in NASH: What Is The Update?


Mazen Noureddin, MD, MHSc
Director, Fatty Liver Program
Karsh Division of Gastroenterology and Hepatology
Comprehensive Transplant Center
Cedars-Sinai Medical Center Los Angeles, CA
Mazen Noureddin, MD, MHSc
Director, Fatty Liver Program

Dr. Mazen Noureddin is the founding Director of Cedars-Sinai’s Fatty Liver Program in Los Angeles, California. The research of Mazen Noureddin, MD, MHSc, focuses on the underlying mechanisms of non- alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities, non-invasive biomarkers, and exploring new treatments. He has conducted several original studies that have been featured in publications in Gastroenterology, Journal of Hepatology, Gut, Hepatology, The American Journal of Gastroenterology, and many others. The Fatty Liver Program at Cedars- Sinai is conducting a number of breakthrough studies and clinical trials targeting new therapies in patients NAFLD and NASH, including those with advanced fibrosis and cirrhosis.

Rohit Loomba, MD, MHSc
Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology and Vice Chief, Division of Gastroenterology
Adjunct Professor, Division of Epidemiology University of California at San Diego San Diego, CA
Rohit Loomba, MD, MHSc
Director, NAFLD Research Center

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging endpoints, and integrated OMICs using microbiome, metabolome, and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 50 clinical trials conducted worldwide. He holds a patent on non-invasive biomarkers of NASH and fibrosis.

His research is funded by the National Institutes of Health including two R01s, three U01 (two NIDDK and one from NIAAA), core director of P30 (NIDDK) and project director P01 (NHLBI) grant mechanisms, Foundation of NIH, National Science Foundation, as well as several investigator-initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases and is the elected member to the National Board of Directors of the American Liver Foundation.

He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in gastroenterology and hepatology. He recently completed a 5-year term as the Deputy Editor of HEPATOLOGY, the official journal of the AASLD. Currently, he serves as the co-Editor of Alimentary Pharmacology and Therapeutics, an international journal in the field of gastroenterology and hepatology.

Dr. Loomba has published more than 300 manuscripts and has an H-index of 92. He is among the top 1% of the globally highly cited scientists across all fields in 2019 and 2020 by Web of Science. He is an elected member of American Society of Clinical Investigation.

Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
President, Inova Medicine Services
Chairman, Clinical Research, Inova Health System
Professor and Chairman of Department of Medicine Inova Fairfax Medical Campus Falls Church, VA
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
President, Inova Medicine Services

Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY, USA. He completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, USA, while earning his Master of Public Health degree from San Diego State University School of Public Health, San Diego, California, USA. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, USA, before establishing the Center for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to non-alcoholic fatty liver disease (NAFLD) and outcomes research in liver disease. He has served as Vice President of Research for Inova Health System and currently serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation (2018-Present) and the Board of Inova Health System Foundation (2011-Present). Dr. Younossi was appointed by Governors T. Kaine and B. McDonnell of Virginia to the Board of Directors of Virginia Biotechnology Research Partnership Authority (2008-2014). He also served on the Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors, America Heart Association, Mid-Atlantic Affiliate (2010-2012) and Board of the American College of Gastroenterology Institute for Clinical Research & Education (2013-Present). He has served on multiple committees for American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastrointestinal Association, and George Mason University as well as on numerous committees at Inova Fairfax Hospital and Inova Health System.

Dr. Younossi pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. In addition to research and administrative duties, Dr. Younossi has been actively involved in teaching students, residents, and fellows. He has also served as Chair, Director or faculty of a number of international scientific, and CME-related courses.

Dr. Younossi specializes in hepatology and gastroenterology and has authored over 510 articles, 3 books, 6 journal supplements, over 25 book chapters, and over 800 abstracts at the international scientific meetings. He is a highly sought-after speaker providing over 420 faculty lectures in national and international meetings. His academic productivity has led to an H-index of 82. Dr. Younossi also serves as the co-editor of Liver International, Associate Editor of Journal of Hepatology, and on the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Statement of Need

Non-alcoholic steatohepatitis (NASH) is a severe and potentially life-threatening form of non-alcoholic fatty liver disease (NAFLD) that has emerged as a major health and societal burden in the United States. Of the estimated one in four individuals who have NAFLD, one in five has NASH, and although the pathogenesis of NAFLD and NASH have not been fully elucidated, it is a result of several pathways that may lead to advanced fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death.

This CME Outfitters enduring material features a renowned panel of experts highlighting the underlying mechanisms of NASH via innovative augmented reality (AR) animations and presenting real-world case scenarios to share clinical insights on how to choose appropriate non-invasive diagnostic modalities, as well as translate latest data on emerging targeted therapies and their implications for clinical practice.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Summarize the epidemiology of NAFLD and NASH and the factors driving the progression to advanced fibrosis.
  • Determine candidates for liver biopsy versus noninvasive modalities for the staging of fibrosis in NASH.
  • Evaluate the clinical significance of the latest clinical data on emerging targeted therapies for NASH.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize the epidemiology of NAFLD and NASH and the factors driving the progression to advanced fibrosis.
  • Identify candidates for liver biopsy versus noninvasive modalities for the staging of fibrosis in NASH.
  • Evaluate the clinical significance of the latest clinical data on emerging targeted therapies for NASH.

Financial Support

Supported by an educational grant from Intercept Pharmaceuticals, Inc.

Target Audience

Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (CNE)

Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hour(s).

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit. Jump to Activity UAN.
Activity UAN: 0376-0000-20-150-H01-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; Shire; and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; EchosensTM North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; Roche Diagnostics, North America; and Siemens. He is a stock shareholder (directly purchased) of Ananetos; and Viking Therapeutics, Inc.

Dr. Loomba reports that his institution has received grant support from Allergan; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Cirius Therapeutics; Eli Lilly and Company; Galectin Therapeutics Inc.; Galmed Pharmaceuticals Ltd.; GE Healthcare Life Sciences; Genfit; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; GRAIL, Inc.; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; NGM Biopharmaceuticals; NuSirt Biopharma; Pfizer Inc.; pH Pharma Co., Ltd.; Prometheus Laboratories Inc.; and Siemens. He is a consultant or advisory board member for Alnylam Pharmaceuticals,Inc./Regeneron Pharmaceuticals Inc.; Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bird Rock Bio; Boehringer Inghelheim; Bristol-Myer Squibb Company; Celgene Corporation; Cirius Therapeutics; CohBar, Inc.; Conatus Pharmaceuticals Inc.; Eli Lilly and Company; Galmed Pharmaceuticals Ltd.; Gemphire Therapeutics Inc.; Gilead Sciences, Inc.; Glimpse Bio; GNI Group Ltd.; GRI Bio; Inipharm, Inc.; Intercept Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Metacrine, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Prometheus Laboratories Inc.; Promethera? Biosciences; Sanofi-Aventis U.S. LLC; Siemens; and Viking Therapeutics, Inc. He receives other financial or material support as the co-founder of Liponexus, Inc.

Dr. Younossi reports that he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; and Siemens. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; and Terns Pharmaceuticals, Inc.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Evan Luberger (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-150-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Saturday Morning Coffee with Experts in NASH: What Is The Update?
Event Date: 11/10/2020